Innovative Access Agreements: A potential payer solution for Cell & Gene Therapies
A US and EU perspective
By Daniele Severi Bruni & Sophie Schmitz
What’s the idea?
Payer concerns over increasing cost of therapies and uncertainty of clinical data has led to a growing interest in market access tools. Experts Daniele Severi Bruni partner at MKO and Sophie Schmitz from Partners4Access discuss this potential payer solution for Cell & Gene Therapies.